{"filing":{"accession_number":"0001193125-26-301414","cik":"0001098972","ticker":"AGEN","company_name":"AGENUS INC","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"d111026d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1098972/000119312526301414/d111026d8k.htm"},"events":[{"id":17438,"run_id":15613,"accession_number":"0001193125-26-301414","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Agenus entered into a Securities Purchase Agreement for a private placement of approximately $85 million in upfront gross proceeds plus up to $255 million upon warrant exercise, totaling up to $340 million. The company will issue 23,035,227 shares of common stock (or pre-funded warrants), Series A purchase warrants for 21,144,277 shares, and Series B purchase warrants for 33,797,214 shares to institutional investors including Commodore Capital, RA Capital, TCGX, Invus, and Ligand, representing substantial dilution to existing shareholders.","company_name":"AGENUS INC","ticker":"AGEN","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":15908,"accession_number":"0001193125-26-301414","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Agenus entered into a Securities Purchase Agreement for a private placement of common stock, pre-funded warrants, and purchase warrants totaling approximately $85 million in upfront gross proceeds with up to $255 million additional upon warrant exercise. This is a classic dilutive equity issuance to institutional investors (Commodore Capital, RA Capital, TCGX, Invus, Ligand) structured as a PIPE-like transaction with warrants. The filing explicitly discloses 23,035,227 shares (or pre-funded warrants), Series A warrants for 21,144,277 shares, and Series B warrants for 33,797,214 shares, representing substantial dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:46:08.021163+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15909,"accession_number":"0001193125-26-301414","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Agenus announced a private placement of approximately $85 million in upfront gross proceeds plus up to $255 million upon exercise of purchase warrants, totaling up to $340 million. The company will issue 23,035,227 shares of common stock (or pre-funded warrants), Series A purchase warrants, and Series B purchase warrants in a transaction not registered under the Securities Act and sold pursuant to Regulation D. This is a classic dilutive equity issuance to raise capital, material to investors assessing ownership dilution and the company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:46:08.021163+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15910,"accession_number":"0001193125-26-301414","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a private placement of approximately $85 million in upfront gross proceeds plus up to $255 million upon warrant exercise, totaling up to $340 million. The company is issuing 23,035,227 shares of common stock (or pre-funded warrants), Series A purchase warrants, and Series B purchase warrants in a Regulation D private placement. This is a material dilutive equity issuance to raise capital, structured with warrants that provide additional dilution upon exercise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:46:08.021163+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15911,"accession_number":"0001193125-26-301414","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a private placement of approximately $85 million in upfront gross proceeds plus up to $255 million in warrant exercises, totaling up to $340 million. The company is issuing common stock (or pre-funded warrants), Series A warrants, and Series B warrants to investors including Commodore Capital, RA Capital, and others. While the Item 8.01 framing emphasizes the strategic clinical prioritization of BOT+BAL and the ROBBIN trial, the core transaction is a dilutive equity issuance that raises capital through unregistered securities. The filing explicitly states the securities are being sold in a private placement under Regulation D and are not registered under the Securities Act, which is characteristic of dilutive issuances. The company also agreed to register resale rights and to expand its board to accommodate investor directors, further confirming the equity capital-raise nature of the transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:46:08.021163+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15908,"accession_number":"0001193125-26-301414","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Agenus entered into a Securities Purchase Agreement for a private placement of common stock, pre-funded warrants, and purchase warrants totaling approximately $85 million in upfront gross proceeds with up to $255 million additional upon warrant exercise. This is a classic dilutive equity issuance to institutional investors (Commodore Capital, RA Capital, TCGX, Invus, Ligand) structured as a PIPE-like transaction with warrants. The filing explicitly discloses 23,035,227 shares (or pre-funded warrants), Series A warrants for 21,144,277 shares, and Series B warrants for 33,797,214 shares, representing substantial dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:46:08.021163+00:00","company_name":"AGENUS INC","ticker":"AGEN","filing_date":"2026-07-13"},{"id":15909,"accession_number":"0001193125-26-301414","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Agenus announced a private placement of approximately $85 million in upfront gross proceeds plus up to $255 million upon exercise of purchase warrants, totaling up to $340 million. The company will issue 23,035,227 shares of common stock (or pre-funded warrants), Series A purchase warrants, and Series B purchase warrants in a transaction not registered under the Securities Act and sold pursuant to Regulation D. This is a classic dilutive equity issuance to raise capital, material to investors assessing ownership dilution and the company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:46:08.021163+00:00","company_name":"AGENUS INC","ticker":"AGEN","filing_date":"2026-07-13"},{"id":15910,"accession_number":"0001193125-26-301414","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a private placement of approximately $85 million in upfront gross proceeds plus up to $255 million upon warrant exercise, totaling up to $340 million. The company is issuing 23,035,227 shares of common stock (or pre-funded warrants), Series A purchase warrants, and Series B purchase warrants in a Regulation D private placement. This is a material dilutive equity issuance to raise capital, structured with warrants that provide additional dilution upon exercise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:46:08.021163+00:00","company_name":"AGENUS INC","ticker":"AGEN","filing_date":"2026-07-13"},{"id":15911,"accession_number":"0001193125-26-301414","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a private placement of approximately $85 million in upfront gross proceeds plus up to $255 million in warrant exercises, totaling up to $340 million. The company is issuing common stock (or pre-funded warrants), Series A warrants, and Series B warrants to investors including Commodore Capital, RA Capital, and others. While the Item 8.01 framing emphasizes the strategic clinical prioritization of BOT+BAL and the ROBBIN trial, the core transaction is a dilutive equity issuance that raises capital through unregistered securities. The filing explicitly states the securities are being sold in a private placement under Regulation D and are not registered under the Securities Act, which is characteristic of dilutive issuances. The company also agreed to register resale rights and to expand its board to accommodate investor directors, further confirming the equity capital-raise nature of the transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T10:46:08.021163+00:00","company_name":"AGENUS INC","ticker":"AGEN","filing_date":"2026-07-13"}]}